Wolfram Syndrome Treatment Market

Wolfram Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Wolfram syndrome is an inherited condition characterized by the childhood onset of diabetes mellitus, diabetes insipidus, and optic atrophy, causing gradual loss of vision and deafness
Wolfram syndrome is a rare neurodegenerative disease that is considered as a prototype of the endoplasmic reticulum disease. There are two identified causative agents, WFS1 and WFS2, responsible for Wolfram syndrome.
Other major symptoms of Wolfram syndrome are bowel & bladder dysfunction, causing vestibular deficits, temperature regulation problems, olfactory defects, and decreased balance. As per research published by National Institute of Health (NIH), 65% of the people suffering from Wolfram syndrome suffer from sensorineural deafness and 70% of Wolfram syndrome patients are expected to suffer from diabetes insipidus condition.
Moreover, 60% to 90% of Wolfram syndrome patients are likely to suffer with urinary tract condition. About 60% of Wolfram syndrome patients are likely to develop neurological disorder. Several patients suffering from Wolfram syndrome are expected to develop insulin-dependent diabetes mellitus before the age of 16, which accounted for 87% of the total patient population.

Rise in awareness about Wolfram syndrome and standard diagnosis rate of Wolfram syndrome, increasing incidences of the diabetes mellitus are a few factors that are anticipated to propel the market globally
Clinical trials are underway to investigate differentiation in type 1 and type 2 wolfram syndrome to diagnosis and prognosis of the disease for different patient population. Investments in research & development to identify the treatment of the syndrome is also estimated to propel the market globally.
Wolfram syndrome affects around 1 in 200,000 to 500,000 people across globe and as per medical experts, around 15,000 to 30,000 patients are estimated to be suffering from Wolfram syndrome. In the U.S., Wolfram syndrome was likely to have affected between 1,000 and 2,000 people in 2019. These statistics indicate that patients suffering from Wolfram syndrome die before the age of 40.

North America is anticipated to account for a notable share of the market during the forecast period, followed by Europe. Rise in number of people suffering from diabetes mellitus in the U.S. drives the attention toward diagnosis of Wolfram syndrome. Increase in diagnosis and research for development for the treatment of Wolfram syndrome disease is another major factor propelling the market in the region. In North America, wolfram syndrome affects around 1 in 100,000 population.
In Europe, the incidence of Wolfram syndrome is increasing and is recognized as a rare disease in the region. Prevalence of Wolfram syndrome is affecting around 5 per 10,000 population in the region. In the U.K., the prevalence of Wolfram syndrome was estimated to be 1 in 770,000 in 2018.
Technological advancements, standard diagnostic tools for detection of the rare diseases, rising awareness, and accessibility to healthcare infrastructure are a few factors that are estimated to fuel the Wolfram syndrome treatment market during the forecast period.

Global Wolfram Syndrome Treatment Market, by Type

Global Wolfram Syndrome Treatment Market, by Treatment

Global Wolfram Syndrome Treatment Market, by Distribution Channel

Global Wolfram Syndrome Treatment Market, by Region

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia & New Zealand
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa